Influence of erythropoietin on microvesicles derived from mesenchymal stem cells protecting renal function of chronic kidney disease

摘要: Mesenchymal stem cells (MSCs) play a central role in the remediation of cell and tissue damage. Erythropoietin (EPO) may enhance beneficial influence MSCs during recovery from organ injuries. Microvesicles (MVs) released contribute to restoration kidney We studied EPO on MVs derived MSCs, protective effects these factors subjects with chronic disease (CKD). The untreated (MSC-MVs) or incubated different concentrations (1, 10, 100, 500 IU/ml EPO-MVs) were used treat renal injury unilateral ureteral obstruction (UUO) vivo, transforming growth factor-β1 (TGF-β1)-induced fibrosis human proximal tubular epithelial (HK2) line vitro. Western blot reverse transcription polymerase chain reaction (RT-PCR) analyses evaluate expression mesenchymal markers HK2 cells. Flow cytometry was assess apoptosis within cells, microRNA (miRNA) microarray assays determine profiles miRNA MSC-MVs EPO-MVs. Compared (untreated), there significant increase number EPO-MVs treated 1–100 EPO, had greater benefit UUO mice days 7 14. Moreover, better restorative effect following TGF-β1-induced at 24 h 48 h. flow results revealed that both types MVs, especially EPO-MVs, an important anti-apoptotic TGF-β1. changed 212 miRNAs (fold-change ≥ 1.5), including miR-299, miR-499, miR-302, miRNA-200, 70.28 % changes involved upregulation. have contributed their enhanced compared MSC-MVs. There dose-dependent level range EPO. Although protect fibrosis-related damage, is superior